<DOC>
	<DOCNO>NCT02579928</DOCNO>
	<brief_summary>The purpose study determine tolerability short-term efficacy single ketamine infusion treatment adolescent 1 ) medication-refractory major depressive disorder ( MDD ) and/or 2 ) medication-refractory anxiety disorder ( social anxiety disorder , panic disorder , generalize anxiety disorder and/or separation anxiety disorder ) .</brief_summary>
	<brief_title>Ketamine Infusion Adolescent Depression Anxiety</brief_title>
	<detailed_description>We conduct crossover trial many 36 adolescent ( 18 MDD 18 anxiety disorder ) give single infusion ketamine ( study drug ) midazolam ( active control ) . MDD symptoms anxiety symptom monitor two-week period . If applicable , comorbid school refusal symptom also monitor two-week period cohort . A 2-week washout period require infusion dos . Our primary outcomes 1 ) improvement MDD symptom ( measure Montgomery-Asberg Depression Rating Scale , revise ( MADRS ) score ) 1 day infusion , cohort subject enrol MDD arm trial 2 ) improvement anxiety symptom ( measure Multimodal Anxiety Scale Children ( MASC ) acute physical symptom subscale ) cohort subject enrol anxiety disorder arm trial .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Inclusion : MDD Cohort : Meet DSM5 criterion Major Depressive Disorder structure interview ( MINIKID ) CDRSR score &gt; 40 . Failure achieve remission least 1 adequate prior antidepressant trial ( e.g . SSRI , SNRI , TCA ) , mean least 8 week therapeutic dosing , include least 4 week stable dose . Anxiety Cohort : Meet DSM5 criterion follow anxiety disorder : Social Anxiety Disorders , Generalized Anxiety Disorder , Separation Anxiety Disorder and/or Panic Disorder structure interview ( MINIKID ) ADIS Clinical Severity Rating â‰¥4 ( moderately severe ) 4 include anxiety disorder Failure achieve remission least 1 adequate prior anxiolytic medication trial ( e.g . SSRI , SNRI , TCA ) , mean least 8 week therapeutic dosing , include least 4 week stable dose . Failure achieve remission previous CBT subject decline current CBT therapy Both cohort : Stable psychiatric medication dose month prior enrollment . Subjects may continue engage ongoing psychotherapy . Medically neurologically healthy basis physical examination medical history . Parents able provide write informed consent adolescent must additionally provide assent . Exclusion : Current inpatient hospitalization active suicidal ideation require referral inpatient hospitalization safety . History psychotic disorder manic episode diagnose MINIKID History substance dependence diagnosis MINIKID ( exclude tobacco ) positive urine toxicology . Pregnancy ( urine pregnancy test day scan menstruate girl ) . Inability provide write informed consent accord Yale Human Investigation Committee ( HIC ) guideline English .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ketamine</keyword>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Anxiety</keyword>
	<keyword>School refusal</keyword>
	<keyword>Suicide</keyword>
	<keyword>Generalized Anxiety</keyword>
	<keyword>Suicidal Ideation</keyword>
</DOC>